IMV - IMV （IMV Inc.） IMVIMVのチャート
IMVの企業情報
| symbol | IMV |
|---|---|
| 会社名 | IMV Inc （IMV） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- IMVはカナダのバイオ医薬品企業。主に免疫細胞療法に焦点を当て事業を行う。独自のワクチン強化プラットフォ―ムであるDepoVaxに基づき、がんのT細胞活性化療法や、呼吸器合胞体ウイルスのためのワクチン候補の開発を行う。また、DepoVaxがマラリアおよびジカウイルスに対処する可能性を評価する臨床プロジェクトも手掛ける。本社所在地はノバ・スコシア州。 |
| 本社所在地 | 1344 Summer Street Suite 412 Halifax Nova Scotia B3H 0A8 CAN |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 39203 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 33人 |
| url | www.imvaccine.com |
| nasdaq_url | https://www.nasdaq.com/symbol/imv |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 5.5 |
| 時価総額（marketcap） | 246913392 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
IMVのテクニカル分析
IMVのニュース
IMV Stock Falls After Interim Data From Lead Candidate In Blood Cancer Subtype 2023/02/13 15:29:26 Benzinga
IMV Inc (NASDAQ: IMV ) announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (MVP-S), in combination with Merck & Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab) for relapsed, refractory Diffuse Large B Cell Lymphoma (r/r DLBCL). Related: Full story available on Benzinga.com
US stocks closed lower, Dow Jones down 2.25% 2022/12/16 02:15:40 InstaForex
At closing bell on the New York Stock Exchange, the Dow Jones fell 2.25 percent to a one-month low, the S&P 500 index shed 2.49 percent and the NASDAQ Composite fell 3.23 percent. The leaders among Dow Jones index components in Thursday trading were shares of Verizon Communications Inc. which gained 0.32p (0.85%) to close at 37.77. Chevron Corp dropped 1.29p (0.75%) to close at 171.04. Walmart Inc shares shed 1.31p (0.89%) to close at 145.36. International Business Machines were the least gainers, with shares falling 7.50p (5.00%) to close the session at 142.36. Shares of Apple Inc soared 6.71p (4.69%) to 136.50, while Intel Corporation dropped 1.11p (3.93%) to 27.15. The gainers among S&P 500 index components in today''s trading were Lennar Corporation shares, which gained 3.82% to 94.29, DR Horton Inc. which gained 3.49% to close at 90.45 and Align Technology Inc. which gained 3.15% to close the session at 201.97. Western Digital Corporation shares were the least gainers, dropping 10.
IMV Shareholders Approve Reverse Stock Split at 88% 2022/12/07 21:05:15 Financial Post
IMV’s common shares expected to begin trading on a split-adjusted basis on December 13, 2022 DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass. — IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that […]
IMV Shareholders Approve Reverse Stock Split at 88% 2022/12/07 21:05:00 Business Wire
IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies
Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year 2022/12/01 13:05:00 Kwhen Finance
Shimadzu Medical Systems USA receives an IMV ServiceTrak Award in the R/F Systems category 2022/11/28 15:40:00 Kwhen Finance
IMV Inc. Announces Third Quarter 2022 Financial and Operational Results 2022/11/10 21:05:00 Kwhen Finance
IMV Provides an Update on The VITALIZE Trial 2022/09/30 11:05:00 Wallstreet:Online
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today provided an update on the open-label VITALIZE study evaluating its lead product maveropepimut-S (MVP-S) in combination with pembrolizumab and intermittent low-dose cyclophosphamide (CPA) in
IMV to cut ~33% workforce amid reorganization 2022/09/15 13:14:29 Seeking Alpha
IMV (IMV) said it was undertaking a reorganization and reducing its workforce by nearly one third.The company will focus on its DPX platform and advance its lead DPX asset…
IMV GAAP EPS of -$0.12, revenue of $0.03M 2022/08/11 11:30:28 Seeking Alpha
IMV press release (IMV): Q2 GAAP EPS of -$0.12.Revenue of $0.03M (-25.0% Y/Y).On June 30, 2022, the Company had cash and cash equivalents of $31.1M and working capital of $27.7M,…
Earnings Scheduled For August 11, 2022 2022/08/11 09:09:16 Benzinga
Companies Reporting Before The Bell • Magic Software (NASDAQ: MGIC ) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. • Dingdong (Cayman) (NYSE: DDL ) is likely to report earnings for its second quarter. • Evelo Biosciences (NASDAQ: EVLO ) is projected to report earnings for its second quarter. • Affimed (NASDAQ: AFMD ) is estimated to report quarterly loss at $0.17 per share on revenue of $8.67 million. • CorEnergy Infr Trust (NYSE: CORR ) is expected to report earnings for its second quarter. • Six Flags Entertainment (NYSE: SIX ) is expected to report earnings for its second quarter. • Where Food Comes From (NASDAQ: WFCF ) is projected to report earnings for its second quarter. • BurgerFi International (NASDAQ: BFI ) is estimated to report earnings for its second quarter. • Smith-Midland (NASDAQ: SMID ) is expected to report earnings for its second quarter. • Kala Pharmaceuticals (NASDAQ: KALA ) is expected to report earnings for its second quarter.
IMV receives Nasdaq non-compliance letter 2022/07/08 20:14:01 Seeking Alpha
IMV (IMV) received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing.Company may be eligible for an additional 180 calendar…
IMV Inc. Announces First Quarter 2022 Financial and Operational Results 2022/05/13 11:05:00 Business Wire
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the first quarter ended March 31, 2022. “A top priority for 2022 is to accelerate MVP-S towards registration trials. The positive clinical data we presented on MVP-S in comb
IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022 2022/05/06 11:05:00 Business Wire
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the company’s 2022 first quarter financial and operational results. Financial analysts are invited to join the con